These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 12833009)

  • 41. 8-MOP PUVA for psoriasis: a comparison of a minimal phototoxic dose-based regimen with a skin-type approach.
    Collins P; Wainwright NJ; Amorim I; Lakshmipathi T; Ferguson J
    Br J Dermatol; 1996 Aug; 135(2):248-54. PubMed ID: 8881668
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PUVA therapy for polymorphous light eruptions: comparison of systemic methoxsalen and topical trioxsalen regimens and evaluation of local protective mechanisms.
    Jansén CT; Karvonen J; Malmiharju T
    Acta Derm Venereol; 1982; 62(4):317-20. PubMed ID: 6183864
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correlation between bathing time and photosensitivity in 8-methoxypsoralen (8-MOP) bath PUVA.
    Dolezal E; Seeber A; Hönigsmann H; Tanew A
    Photodermatol Photoimmunol Photomed; 2000 Aug; 16(4):183-5. PubMed ID: 11019944
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alopecia areata treatment with a phototoxic dose of UVA and topical 8-methoxypsoralen.
    Mohamed Z; Bhouri A; Jallouli A; Fazaa B; Kamoun MR; Mokhtar I
    J Eur Acad Dermatol Venereol; 2005 Sep; 19(5):552-5. PubMed ID: 16164707
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A reappraisal of the use of 5-methoxypsoralen in the therapy of psoriasis.
    Calzavara-Pinton P; Ortel B; Carlino A; Honigsmann H; De Panfilis G
    Exp Dermatol; 1992 Jul; 1(1):46-51. PubMed ID: 1344660
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized, double-blind comparison of 1 mg/L versus 5 mg/L methoxsalen bath-PUVA therapy for chronic plaque-type psoriasis.
    Vongthongsri R; Konschitzky R; Seeber A; Treitl C; Hönigsmann H; Tanew A
    J Am Acad Dermatol; 2006 Oct; 55(4):627-31. PubMed ID: 17010742
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Miniature swine model of phototoxicity testing.
    Leigh H; Forbes PD; Lawson C; Kim DY; White D; Brown LD; Wehmeier DR; Liu J; Bouchard GF
    Photodermatol Photoimmunol Photomed; 2012 Feb; 28(1):34-41. PubMed ID: 22212001
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cutaneous phototoxicity due to psoralens.
    Gange RW; Parrish JA
    Natl Cancer Inst Monogr; 1984 Dec; 66():117-26. PubMed ID: 6531018
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of oral psoralen-UV-A with a portable tanning unit at home vs hospital-administered bath psoralen-UV-A in patients with chronic hand eczema: an open-label randomized controlled trial of efficacy.
    van Coevorden AM; Kamphof WG; van Sonderen E; Bruynzeel DP; Coenraads PJ
    Arch Dermatol; 2004 Dec; 140(12):1463-6. PubMed ID: 15611423
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of the carcinogenic potential of trioxsalen bath PUVA and oral methoxsalen PUVA. A preliminary report.
    Lindelöf B; Sigurgeirsson B; Tegner E; Larkö O; Berne B
    Arch Dermatol; 1992 Oct; 128(10):1341-4. PubMed ID: 1417020
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bath-5-methoxypsoralen-UVA therapy for psoriasis.
    Calzavara-Pinton PG; Zane C; Carlino A; De Panfilis G
    J Am Acad Dermatol; 1997 Jun; 36(6 Pt 1):945-9. PubMed ID: 9204060
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of minimal phototoxic dose following 8-methoxypsoralen bath: maximal reaction on average after 5 days.
    Behrens-Williams S; Gruss C; Grundmann-Kollmann M; Peter RU; Kerscher M
    Br J Dermatol; 2000 Jan; 142(1):112-5. PubMed ID: 10651704
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Psoralen-ultraviolet A-induced erythema: sensitivity correlates with the concentrations of psoralen in suction blister fluid.
    Yeo UC; Shin JH; Yang JM; Park KB; Kim MM; Bok HS; Lee ES
    Br J Dermatol; 2000 Apr; 142(4):733-9. PubMed ID: 10792224
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Influence of retinoids on the bioavailability of methoxy-8-psoralen].
    Beani JC; Bonnot D; Berthod F; Boitard M; Reymond JL; Beriel H; Amblard P
    Ann Dermatol Venereol; 1991; 118(4):273-5. PubMed ID: 2069337
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Difference in topical and systemic reactivity of psoralens: determinations of epidermal and serum levels.
    Kornhauser A; Wamer WG; Giles AL
    Natl Cancer Inst Monogr; 1984 Dec; 66():97-101. PubMed ID: 6531046
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of UVA irradiation on the epidermal melanocyte after 8-MOP and TMP administration.
    Park YK; Hann SK; Cho MY; Hahn CS; Kim HJ; Hong KT
    J Dermatol Sci; 1990 Sep; 1(5):355-9. PubMed ID: 2127374
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oral vs. bath PUVA using 8-methoxypsoralen for chronic palmoplantar eczema.
    Tzaneva S; Kittler H; Thallinger C; Hönigsmann H; Tanew A
    Photodermatol Photoimmunol Photomed; 2009 Apr; 25(2):101-5. PubMed ID: 19292787
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Determination of 8-methoxypsoralen kinetics: a relevant factor in the treatment of psoriasis by psoralen plus ultraviolet A therapy.
    Bonnot D; Béani JC; Boitard M; Reymond JL; Bériel H; Amblard P
    Photodermatol Photoimmunol Photomed; 1994 Feb; 10(1):33-7. PubMed ID: 8180098
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Treatment of plaque-type psoriasis with cream-PUVA therapy].
    Steinmeyer K; Grundmann-Kollmann M; Podda M; Kaufmann R
    Hautarzt; 2001 Oct; 52(10):885-7. PubMed ID: 17690819
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inefficacy of topical methoxalen plus UVA for palmoplantar pustulosis.
    Jansén CT; Malmiharju T
    Acta Derm Venereol; 1981; 61(4):354-6. PubMed ID: 6173996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.